<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02735902</url>
  </required_header>
  <id_info>
    <org_study_id>LOCAL/2016/GC-01</org_study_id>
    <secondary_id>2016-000352-98</secondary_id>
    <nct_id>NCT02735902</nct_id>
  </id_info>
  <brief_title>Anticoagulation Alone Versus Anticoagulation and Aspirin Following Transcatheter Aortic Valve Interventions (1:1)</brief_title>
  <acronym>AVATAR</acronym>
  <official_title>Anticoagulation Alone Versus Anticoagulation and Aspirin Following Transcatheter Aortic Valve Interventions - an Open, Multicenter Randomized Controlled Trial With Two Parallel Arms (1:1)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Nīmes</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medtronic</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Nīmes</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of this study is to demonstrate that a single anticoagulant therapy is
      superior to a combination of anticoagulant and antiplatelet therapy on the net clinical
      benefit estimated at 12 months after a Transcatheter Aortic Valve Intervention (TAVI)
      according to BARC2 criteria (bleeding complications; Mehran et al 2011) and VARC2 (other
      complications; Kappetein et al 2012)..
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The secondary objectives of this study are to evaluate the following at 3 months, 6 months
      and 12 months after TAVI in both groups:

        1. Mortality (all causes).

        2. Cardiovascular mortality.

        3. The occurrence of myocardial infarction.

        4. The occurrence of stroke.

        5. The occurrence of valve thrombosis.

        6. The occurrence of major bleeding (BARC ≥ 3).

        7. The occurrence of minor bleeding (2 ≤ BARC &lt;3).

        8. Treatment compliance.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2017</start_date>
  <completion_date type="Anticipated">April 2020</completion_date>
  <primary_completion_date type="Anticipated">April 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Composite outcome of the following events: death from any cause, myocardial infarction, stroke all causes, valve thrombosis and hemorrhage ≥ 2 as defined by the VARC 2 (Valve Academic Research Consortium scale).</measure>
    <time_frame>Month 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>All cause death according to the VARC 2 criteria</measure>
    <time_frame>month 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All cause death according to the VARC 2 criteria</measure>
    <time_frame>month 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All cause death according to the VARC 2 criteria</measure>
    <time_frame>month 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All cause death according to the VARC 2 criteria</measure>
    <time_frame>month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death due to cardio-vascular causes according to the VARC 2 criteria</measure>
    <time_frame>month 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death due to cardio-vascular causes according to the VARC 2 criteria</measure>
    <time_frame>month 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death due to cardio-vascular causes according to the VARC 2 criteria</measure>
    <time_frame>month 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death due to cardio-vascular causes according to the VARC 2 criteria</measure>
    <time_frame>month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial infarction according to VARC 2 criteria</measure>
    <time_frame>month 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial infarction according to VARC 2 criteria</measure>
    <time_frame>month 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial infarction according to VARC 2 criteria</measure>
    <time_frame>month 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial infarction according to VARC 2 criteria</measure>
    <time_frame>month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stroke (all cause) according to the VARC 2 criteria</measure>
    <time_frame>month 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stroke (all cause) according to the VARC 2 criteria</measure>
    <time_frame>month 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stroke (all cause) according to the VARC 2 criteria</measure>
    <time_frame>month 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stroke (all cause) according to the VARC 2 criteria</measure>
    <time_frame>month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Valve thrombosis according to the VARC 2 criteria</measure>
    <time_frame>Month 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Valve thrombosis according to the VARC 2 criteria</measure>
    <time_frame>Month 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Valve thrombosis according to the VARC 2 criteria</measure>
    <time_frame>Month 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Valve thrombosis according to the VARC 2 criteria</measure>
    <time_frame>Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major hemorrhage (BARC ≥ 3)</measure>
    <time_frame>Month 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major hemorrhage (BARC ≥ 3)</measure>
    <time_frame>Month 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major hemorrhage (BARC ≥ 3)</measure>
    <time_frame>Month 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major hemorrhage (BARC ≥ 3)</measure>
    <time_frame>Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minor hemorrhage (2 ≤ BARC &lt; 3)</measure>
    <time_frame>Month 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minor hemorrhage (2 ≤ BARC &lt; 3)</measure>
    <time_frame>Month 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minor hemorrhage (2 ≤ BARC &lt; 3)</measure>
    <time_frame>Month 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minor hemorrhage (2 ≤ BARC &lt; 3)</measure>
    <time_frame>Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Observance / Modification of treatment (Questionnaire according to Girerd et al. 2001)</measure>
    <time_frame>Month 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Observance / Modification of treatment (Questionnaire according to Girerd et al. 2001)</measure>
    <time_frame>Month 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Observance / Modification of treatment (Questionnaire according to Girerd et al. 2001)</measure>
    <time_frame>Month 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Observance / Modification of treatment (Questionnaire according to Girerd et al. 2001)</measure>
    <time_frame>Month 12</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">170</enrollment>
  <condition>Transcatheter Aortic Valve Replacement</condition>
  <arm_group>
    <arm_group_label>AVK Monotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In this group, patients will receive monotherapy via anti vitamin K; this treatment given corresponds to the anticoagulant treatment the patient was receiving before surgery. A data collection book for monitoring INR values and dates for the next 12 months is given to the patient.
Intervention: AVK</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AVK + Aspirin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In this group, patients will receive combination therapy via anti vitamin K (AVK) and aspirin, whose daily dose is between 75 mg and 100 mg; the AVK treatment administered corresponds to the anticoagulant treatment the patient was receiving before the procedure, monitored and adapted according to current recommendations. A data collection book for monitoring INR values and dates for the next 12 months is given to the patient.
Intervention: AVK Intervention: Aspirin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AVK</intervention_name>
    <description>The AVK treatment will be administered to obtain an International Normalized Ratio between 2 and 3 as recommended.</description>
    <arm_group_label>AVK Monotherapy</arm_group_label>
    <arm_group_label>AVK + Aspirin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin</intervention_name>
    <description>Daily dose is between 75 mg and 100 mg.
Allergic reactions to aspirin may be observed in rare cases. In case of suspicion of allergy, treatment with aspirin is stopped.</description>
    <arm_group_label>AVK + Aspirin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The patient or his/her representative must have given free and informed consent and
             signed the consent

          -  The patient must be insured or beneficiary of a health insurance plan

          -  The patient is available for 12 months of follow-up

          -  The patient underwent a successful transcutaneous implant procedure for an aortic
             valve within the past 24 hours

          -  The patient was receiving anti-vitamin K (AVK) treatment before percutaneous
             implantation of the aortic valve

        Exclusion Criteria:

          -  The patient is participating in another study

          -  The patient is in an exclusion period determined by a previous study

          -  The patient or his/her representative refuses to sign the consent

          -  It is impossible to correctly inform the patient or his/her representative

          -  The patient is pregnant or breastfeeding

          -  The patient has a contraindication (or an incompatible drug association) for a
             treatment used in this study

          -  The patient had a coronary stent for less than 12 months

          -  The patient does not require treatment with aspirin or any other antiplatelet agent

          -  The patient has a history of aspirin allergy

          -  High bleeding risk; such as platelets &lt;50,000 / mm3 during screening, Hb &lt;8.5 g / dL,
             history of intracranial hemorrhage or subdural hematoma, major surgery, parenchymal
             organ biopsy or severe trauma within 30 days before inclusion, active gastrointestinal
             ulcer in the last 3 months;

          -  History of Stroke in the last 3 months;

          -  Moderate or severe liver affection associated with coagulopathy

          -  Active infectious endocarditis

          -  Active tumor treated at the time of inclusion associated with expected survival less
             than one year
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guillaume Cayla, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Centre Hospitalier Universitaire de Nîmes</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Guillaume Cayla, MD, PhD</last_name>
    <phone>+33.(0)4.66.68.31.49</phone>
    <email>guillaume.cayla@chu-nimes.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Carey Suehs, PhD</last_name>
    <phone>+33.(0)4.66.68.67.88</phone>
    <email>carey.suehs@chu-nimes.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Clinique du Millénaire</name>
      <address>
        <city>Montpellier cedex 2</city>
        <zip>34960</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Christophe Piot, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gilles Levy, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>François Rivalland, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU de Montpellier - Hôpital Arnaud de Villeneuve</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Florence Leclercq, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-Christophe Macia, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU de Nîmes - Hôpital Universitaire Carémeau</name>
      <address>
        <city>Nîmes Cedex 09</city>
        <zip>30029</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Guillaume Cayla, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Laurent Schmutz, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Privé les Franciscaines</name>
      <address>
        <city>Nîmes Cedex 1</city>
        <zip>30032</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Eric Maupas, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinique Saint-Pierre</name>
      <address>
        <city>Perpignan</city>
        <zip>66000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Gabriel Robert, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH de Perpignan - Hôpital Saint Jean</name>
      <address>
        <city>Perpignan</city>
        <zip>66046</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Frédéric Targosz, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Delphine Delseny, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Girerd X, Radauceanu A, Achard JM, Fourcade J, Tournier B, Brillet G, Silhol F, Hanon O. [Evaluation of patient compliance among hypertensive patients treated by specialists]. Arch Mal Coeur Vaiss. 2001 Aug;94(8):839-42. French.</citation>
    <PMID>11575214</PMID>
  </reference>
  <reference>
    <citation>Kappetein AP, Head SJ, Généreux P, Piazza N, van Mieghem NM, Blackstone EH, Brott TG, Cohen DJ, Cutlip DE, van Es GA, Hahn RT, Kirtane AJ, Krucoff MW, Kodali S, Mack MJ, Mehran R, Rodés-Cabau J, Vranckx P, Webb JG, Windecker S, Serruys PW, Leon MB. Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document. Eur Heart J. 2012 Oct;33(19):2403-18. doi: 10.1093/eurheartj/ehs255.</citation>
    <PMID>23026477</PMID>
  </reference>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 7, 2016</study_first_submitted>
  <study_first_submitted_qc>April 12, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 13, 2016</study_first_posted>
  <last_update_submitted>December 8, 2017</last_update_submitted>
  <last_update_submitted_qc>December 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>antivitamins K</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

